![]() It displayed high affinity (0.53–1.53 nmol/L) to apixaban, betrixaban, edoxaban and rivaroxaban 1. Andexanet alfa is currently under regulatory review by the European Union and is undergoing clinical development in Japan 1.Īndexanet alfa works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that can lead to can cause serious or fatal bleeding. Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism. ![]() It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban in cases of life-threatening or uncontrolled bleeding. It was developed by Portola Pharmaceuticals and was approved in in May 2018. Ndexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals. It was approved for medical use in the United States in May 2018. It works by binding to rivaroxaban and apixaban. Severe side effects may include blood clots, heart attacks, strokes, or cardiac arrest. Ĭommon side effects include pneumonia and urinary tract infections. It has not been found to be useful for other factor Xa inhibitors. ![]() (Disulfide bridge: H7-H12, H27-H43, H108-L98, H156-H170, H181-H209, L16-L27, L21-元6, 元8-L47, L55-L66, L62-L75, L77-L90)Īnticoagulant reversal (factor Xa inhibitors)Īndexanet alfa, sold under the trade name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. TQKTGIVSGF GRTHEKGRQS TRLKMLEVPY VDRNSCKLSS SFIITQNMFC AGYDTKQEDAĬQGDAGGPHV TRFKDTYFVT GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKAĪNSFLFWNKY KDGDQCETSP CQNQGKCKDG LGEYTCTCLE GFEGKNCELF TRKLCSLDNGĭCDQFCHEEQ NSVVCSCARG YTLADNGKAC IPTGPYPCGK QTLER QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRLKTPITF RMNVAPACLP ERDWAESTLM IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF KVRVGDRNTE
0 Comments
Leave a Reply. |